NCT00552357 Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation
| NCT ID | NCT00552357 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pennsylvania |
| Condition | Primary Graft Dysfunction |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,150 participants |
| Start Date | 2007-12 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,150 participants in total. It began in 2007-12 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Primary graft dysfunction (PGD) is a severe lung complication that can occur in the days after lung transplant surgery. This study will analyze blood samples to determine if high levels of certain chemicals may increase the risk of developing PGD after a lung transplant.
Eligibility Criteria
Inclusion Criteria: * Undergoing lung or combined heart and lung transplantation Exclusion Criteria: * Undergoing combined organ transplantation other than heart and lung transplantation
Contact & Investigator
E.J. Demissie, MSN
📞 215-573-4767
Jason D. Christie, MD
PRINCIPAL INVESTIGATOR
University of Pennsylvania
Frequently Asked Questions
Who can join the NCT00552357 clinical trial?
This trial is open to participants of all sexes, aged 13 Years or older, up to 68 Years, studying Primary Graft Dysfunction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00552357 currently recruiting?
Yes, NCT00552357 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Pennsylvania to inquire about joining.
Where is the NCT00552357 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT00552357 clinical trial?
NCT00552357 is sponsored by University of Pennsylvania. The principal investigator is Jason D. Christie, MD at University of Pennsylvania. The trial plans to enroll 1,150 participants.